12/26/2025
New Findings on Methylene Blue in MS Research and Neurodegeneration.
I am reaching out to share some findings from a recent study on the potential therapeutic effects of methylene blue (MB) in multiple sclerosis (MS)
The study investigates the role of MB in enhancing mitochondrial function and reducing reactive oxygen species (ROS) formation, which are significant factors in the pathogenesis of MS. As you know, oxidative stress and mitochondrial dysfunction contribute to neuronal demyelination and symptom deterioration in MS. We found that at low concentrations, MB robustly suppresses mitochondria-mediated ROS formation.
The results were promising, showing that MB treatment could potentially modulate mitochondrial function and alleviate MS symptoms in our animal model. These findings could pave the way for new therapeutic strategies for neurodegenerative diseases.
Methylene blue is a compound widely researched in central nervous system (CNS) disorders, including CNS injury. Among its various applications, its effects on Alzheimer's disease are particularly well-documented. Our study builds upon this extensive research by exploring MB's role in enhancing mitochondrial function and reducing reactive oxygen species (ROS) formation, which are significant factors in the pathogenesis of MS.
For a detailed read, you can access the full study here: https://www.academia.edu/85697470/Methylene_Blue_Treatment_Enhances_Mitochondrial_Function_and_Locomotor_Activity_in_a_C57BL_6_Mouse_Model_of_Multiple_Sclerosis?email_work_card=title
Donna Marshall
Multiple sclerosis (MS) is a neurodegenerative disease. Although multiple factors are involved in the pathogenesis of MS, there are several lines of evidence that oxidative stress and mitochondrial dysfunction are involved in neuronal demyelination
